Arch, a wound care device startup, raises $7.3M

Arch Therapeutics has reeled in $7.3 million in funding. The medical device startup, based in Cambridge, MA, is developing a synthetic peptide that can be applied to a wound to stop bleeding. MIT came up with the initial technology, Mass High Tech/ Boston Business Journal reports. As the story explains, the wound care market is growing tremendously. But Arch faces many competitors both small and large, including Choice Therapeutics, Ocular Therapeutix, Johnson & Johnson ($JNJ), Smith & Nephew ($SNN), Convatec and KCI.  Story

Suggested Articles

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.

Ortho Clinical Diagnostics has launched a new chemistry system to complete its integrated Vitros XT line of laboratory solutions.

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.